Ángel Mora Segura

Learn More
BACKGROUND Lynch syndrome (LS) is an autosomal dominant inherited cancer syndrome characterized by early onset cancers of the colorectum, endometrium and other tumours. A significant proportion of DNA variants in LS patients are unclassified. Reports on the pathogenicity of the c.1852_1853AA>GC (p.Lys618Ala) variant of the MLH1 gene are conflicting. In this(More)
Somatostatin analogues (SSAs) are indicated to relieve carcinoid syndrome but seem to have antiproliferative effects on neuroendocrine tumours (NETs). This is the first prospective study investigating tumour stabilisation with the long-acting SSA lanreotide Autogel in patients with progressive NETs. This was a multicentre, open-label, phase II trial(More)
Based on the mechanism of action, combining somatostatin analogues (SSAs) with mTOR inhibitors or antiangiogenic agents may provide synergistic effects for the treatment of patients with neuroendocrine tumours (NETs). Herein, we investigate the use of these treatment combinations in clinical practice. This retrospective cross-sectional analysis of patients(More)
The Data-as-a-Service (DaaS, or Data Services) paradigm enables an on-demand, service-based access to data, relying on similar principles to Software-as-a-Service (SaaS). DaaS permits centralized data quality management, a uniform view and access to heterogeneous data, and enables exposing a richer, domain-specific data model to users. Within this context,(More)
Male breast cancer (MBC) is a rare disease that represents <1 % of all breast cancers (BCs). We analyze the results of a multicenter study performed in Spanish familial MBC including family history of hereditary breast and ovarian cancer syndrome (HBOCS) and clinicopathological features. We also study the relationship between BRCA1/BRCA2 mutational status(More)
Meta-models play a pivotal role in Model-Driven Engineering (MDE). They are used to create domain-specific models, and to type model management operations like model transformations or code generators. However, even though creating meta-models is a common activity, it is currently mostly a manual activity, which does not profit from existing knowledge. In(More)
There are clinical situations (CS) in which the use of somatostatin analogs (SSAs) in patients with neuroendocrine tumors (NET) is controversial due to lack of evidence. A Delphi study was conducted to develop common treatment guidelines for these CS, based on clinical practice and expert opinion of Spanish oncologists. A scientific committee identified 5(More)